Defence Therapeutics Correlations

DTCFF Stock

USD 0.41 0.00 0.00%

The current 90-days correlation between Defence Therapeutics and Benitec Biopharma Ltd is 0.04 (i.e., Significant diversification). The correlation of Defence Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Defence Therapeutics Correlation With Market

Good diversification

The correlation between Defence Therapeutics and DJI is -0.04 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Defence Therapeutics and DJI in the same portfolio, assuming nothing else is changed.

The ability to find closely correlated positions to Defence Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Defence Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Defence Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Defence Therapeutics to buy it.

Moving against Defence OTC Stock

0.59	GOOG	Alphabet Class C Buyout Trend	Pair Corr
0.49	AVTE	Aerovate Therapeutics	Pair Corr
0.48	SLF	Sun Life Financial	Pair Corr
0.41	BAC	Bank of America Fiscal Year End 10th of January 2025	Pair Corr
0.37	HNRC	Houston Natural Resources	Pair Corr
0.6	CAT	Caterpillar Fiscal Year End 3rd of February 2025	Pair Corr
0.55	HD	Home Depot	Pair Corr
0.54	CVX	Chevron Corp Sell-off Trend	Pair Corr
0.53	PYPL	PayPal Holdings Aggressive Push	Pair Corr
0.53	AXP	American Express Fiscal Year End 24th of January 2025	Pair Corr
0.5	CSCO	Cisco Systems	Pair Corr
0.45	XOM	Exxon Mobil Corp Fiscal Year End 7th of February 2025	Pair Corr
0.42	DIS	Walt Disney	Pair Corr
0.39	JPM	JPMorgan Chase Fiscal Year End 10th of January 2025	Pair Corr
0.36	DD	Dupont De Nemours Fiscal Year End 4th of February 2025	Pair Corr
0.35	T	ATT Inc Fiscal Year End 22nd of January 2025	Pair Corr

Related Correlations Analysis

	SBHMY	MRES	ALRN	ENLV	PBLA	LIXT	BNTC	CING	TCON	XOMAO
SBHMY		0.07	-0.03	-0.53	-0.88	-0.09	0.69	-0.59	-0.53	0.57	SBHMY
MRES	0.07		-0.74	-0.49	-0.22	0.38	-0.11	0.09	-0.04	-0.24	MRES
ALRN	-0.03	-0.74		0.51	0.17	-0.19	0.2	-0.21	-0.22	0.45	ALRN
ENLV	-0.53	-0.49	0.51		0.7	0.13	-0.16	0.31	0.19	-0.04	ENLV
PBLA	-0.88	-0.22	0.17	0.7		0.18	-0.67	0.71	0.63	-0.6	PBLA
LIXT	-0.09	0.38	-0.19	0.13	0.18		-0.22	0.19	0.24	-0.24	LIXT
BNTC	0.69	-0.11	0.2	-0.16	-0.67	-0.22		-0.6	-0.66	0.75	BNTC
CING	-0.59	0.09	-0.21	0.31	0.71	0.19	-0.6		0.73	-0.73	CING
TCON	-0.53	-0.04	-0.22	0.19	0.63	0.24	-0.66	0.73		-0.82	TCON
XOMAO	0.57	-0.24	0.45	-0.04	-0.6	-0.24	0.75	-0.73	-0.82		XOMAO
	SBHMY	MRES	ALRN	ENLV	PBLA	LIXT	BNTC	CING	TCON	XOMAO

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Please upgrade your account to get full access to Macroaxis premium features

Correlation Matchups

Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.

High positive correlations

XOMAO	+ 0.75	BNTC
TCON	+ 0.73	CING
CING	+ 0.71	PBLA
PBLA	+ 0.7	ENLV
BNTC	+ 0.69	SBHMY
TCON	+ 0.63	PBLA

High negative correlations

PBLA	- 0.88	SBHMY
XOMAO	- 0.82	TCON
ALRN	- 0.74	MRES
XOMAO	- 0.73	CING
BNTC	- 0.67	PBLA
TCON	- 0.66	BNTC

Risk-Adjusted Indicators

There is a big difference between Defence OTC Stock performing well and Defence Therapeutics OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Defence Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
SBHMY	0.64	0.21	0.00	1.46	0.00	0.00	0.00	0.00	25.86
MRES	8.16	1.13	0.10	(2.65)	7.85	(13.92)	16.33	(16.95)	102.95
ALRN	4.30	(0.28)	0.00	(0.36)	0.00	0.00	8.06	(8.77)	41.47
ENLV	3.93	0.01	0.01	0.12	3.97	(5.57)	10.71	(6.15)	35.66
PBLA	7.11	(1.97)	0.00	0.83	0.00	0.00	10.70	(17.30)	88.58
LIXT	4.60	0.29	0.03	(1.14)	5.42	(5.89)	7.24	(8.00)	70.38
BNTC	3.63	0.55	0.12	(4.49)	3.30	(4.82)	10.70	(4.52)	29.78
CING	3.98	(0.22)	0.00	(0.68)	0.00	0.00	8.76	(8.33)	38.00
TCON	6.84	(1.48)	0.00	0.57	0.00	0.00	19.59	(17.77)	52.05
XOMAO	0.24	0.03	(0.26)	2.83	0.22	(0.28)	0.51	(0.40)	2.44

Be your own money manager

Our tools can tell you how much better you can do entering a position in Defence Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Cryptocurrency Center Now

Cryptocurrency Center

Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency

All Next

Launch Module

Defence Therapeutics Corporate Management

Elected by the shareholders, the Defence Therapeutics' board of directors comprises two types of representatives: Defence Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Defence. The board's role is to monitor Defence Therapeutics' management team and ensure that shareholders' interests are well served. Defence Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Defence Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.

Moutih Rafei	VP Director	Profile
Sebastien Plouffe	Pres CEO	Profile
Carrie Cesarone	Co Sec	Profile
Simon Beaudoin	Chief Officer	Profile

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC